Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication (vol 19, 119, 2018)

被引：0
|
作者：
Winner, Paul K. [1 ]
Singh, Rashmi B. Halker [2 ]
Cohen, Joshua M. [3 ]
Yang, Ronghua [3 ]
Yeung, Paul P. [3 ]
Ramirez Campos, Verena [4 ]
机构：
[1] Premiere Res Inst, W Palm Beach, FL 33407 USA
[2] Mayo Clin, Phoenix, AZ USA
[3] Teva Pharmaceut, Frazer, PA USA
[4] Teva Pharmaceut, Buenos Aires, DF, Argentina
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] THE IMPACT OF FREMANEZUMAB ON MIGRAINE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN CHRONIC MIGRAINE PATIENTS WITH CONCOMITANT PREVENTIVE MEDICATION USE
    Lipton, R. B.
    Fitzgerald, T.
    Cohen, J. M.
    Gandhi, S. K.
    CEPHALALGIA, 2018, 38 : 95 - 96
  • [42] The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Chronic Migraine Patients With Concomitant Preventive Medication Use
    Gandhi, Sanjay
    Lipton, Richard
    Cohen, Joshua
    NEUROLOGY, 2019, 92 (15)
  • [43] Number Needed to Treat/Harm for Fremanezumab in Patients Who Had Inadequate Response to 2-4 Prior Migraine Preventive Medication Classes
    Ashina, Messoud
    Cohen, Joshua M.
    Galic, Maja
    Campos, Verena Ramirez
    Du, Evelyn
    Ning, Xiaoping
    Diener, Hans-Christoph
    NEUROLOGY, 2021, 96 (15)
  • [44] NUMBER NEEDED TO TREAT/HARM FOR FREMANEZUMAB IN PATIENTS WHO HAD INADEQUATE RESPONSE TO 2-4 PRIOR MIGRAINE PREVENTIVE MEDICATION CLASSES
    Ashina, Messoud
    Cohen, Joshua M.
    Galic, Maja
    Campos, Verena Ramirez
    Du, Evelyn
    Ning, Xiaoping
    Diener, Hans-Christoph
    CEPHALALGIA, 2020, 40 : 102 - 102
  • [45] Impact of fremanezumab on any acute headache medication use in migraine patients with medication overuse and documented inadequate response to 2-4 migraine preventive medications in the multicentre, randomised, placebo-controlled FOCUS study
    Newman, Lawrence
    Cohen, Joshua M.
    Ramirez-Campos, Verena
    Janka, Lindsay
    Diener, Hans-Christoph
    CEPHALALGIA, 2019, 39 : 238 - 238
  • [46] Impact of Fremanezumab on Migraine-specific Quality of Life in Patients with Medication Overuse and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes in the FOCUS Study
    Mechtler, L. L.
    Ramirez-Campos, V
    Cohen, J. M.
    Janka, L.
    HEADACHE, 2020, 60 : 19 - 19
  • [47] Long-term Efficacy of Erenumab in Patients With Episodic Migranie Who Have Failed Prior Preventive Migraine Therapies
    Reuter, Uwe
    Schwedt, Todd J.
    Kudrow, David
    Paemeleire, Koen
    Zhang, Feng
    Klatt, Jan
    Picard, Hernan
    Chou, Denise E.
    Mikol, Daniel D.
    NEUROLOGY, 2019, 92 (15)
  • [48] Long-Term Impact of Fremanezumab on Response Rate, Acute Headache Medication Use, and Disability in Chronic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
    Silberstein, S. D.
    Kudrow, D.
    Cohen, J. M.
    Gandhi, S. K.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 113 - 113
  • [49] Long-term impact of fremanezumab on response rate, acute headache medication use, and disability in chronic migraine patients with acute medication overuse at baseline: results of a 1-year study
    Silberstein, Stephen D.
    Kudrow, David
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Yang, Ronghua
    Ning, Xiaoping
    Blaiss, Cory
    CEPHALALGIA, 2019, 39 : 214 - 214
  • [50] Fremanezumab impact on disability and MSQOL in patients with inadequate response to 2-4 classes of preventive medications who reverted from chronic to episodic migraine
    Pozo-Rosich, P.
    Cohen, J. M.
    Ning, X.
    Galic, M.
    Yang, R.
    Ramirez-Campos, V.
    Singh, R. Halker
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
12345